41
Views
7
CrossRef citations to date
0
Altmetric
Research Article

The effects of recombinant human erythropoietin given immediately after delivery to women with anaemia

, , , , , & show all
Pages 346-349 | Accepted 15 Apr 2003, Published online: 22 Sep 2008

References

  • Sifakis S, Pharmakides G. Anemia in pregnancy. Ann NY Acad Sci 2000;900:125–36
  • Jelkman W. Biology of erythropoietin. Clin Invest 1994;72:S3–S10
  • Faulds D, Sorkin EM. Epoetin (recombinant human erythropoietin). A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in anemia and the stimulation of erythropoiesis. Drugs 1989;38:863–99
  • Tong EM, Nissenson AR. Erythropoietin and anemia. Semin Nephrol 2001;21:190–203
  • Abels RI. Use of recombinant human erythropoietin in the treatment of anemia in patients who have cancer. Semin Oncol 1992;19(Suppl)8:29–35
  • Mercuriali F, Inghilleri G, Biffi E, et al. Erythropoietin treatment to increase autologous blood donation in patients with low basal hematocrit undergoing elective orthopedic surgery. Clin Invest 1994;72:S16–18
  • Pincus T, Olsen NJ, Russell IJ, et al. Multicenter study of recombinant human erythropoietin in correction of anemia in rheumatoid arthritis. Am J Med 1990;89:161–8
  • Robb N. Concerns of patients, MDs are transforming transfusion medicine. Can Med Assoc J 1996;154:391–6
  • Schreiber GB, Busch MP, Kleinman SH, et al. The risk of trans-fusion-transmitted viral infections. N Engl J Med 1996;334:1685–90
  • Federowicz I, Barrett BB, Andersen JW, et al. Characterization of reactions after transfusion of cellular blood components that are white cell reduced before storage. Transfusion 1996;36:21–8
  • Guest JF, Munro V, Cookson RF. The annual cost of blood transfusions in the United Kingdom. Clin Lab Haematol 1998;20:111–18
  • Braga J, Marques R, Branco A, et al. Maternal and perinatal implications of the use of human recombinant erythropoietin. Acta Obstet Gynecol Scand 1996;75:449–53
  • Huch R, Huch A. Erythropoietin in obstetrics. Hematol Oncol Clin North Am 1994;8:1021–40

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.